HUP0400692A2 - Szubsztituált 7H-pirrolo[2,3-d]pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények - Google Patents

Szubsztituált 7H-pirrolo[2,3-d]pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0400692A2
HUP0400692A2 HU0400692A HUP0400692A HUP0400692A2 HU P0400692 A2 HUP0400692 A2 HU P0400692A2 HU 0400692 A HU0400692 A HU 0400692A HU P0400692 A HUP0400692 A HU P0400692A HU P0400692 A2 HUP0400692 A2 HU P0400692A2
Authority
HU
Hungary
Prior art keywords
group
formula
pyrrolo
substituted
pharmaceutical compositions
Prior art date
Application number
HU0400692A
Other languages
English (en)
Inventor
Arlindo L. Castelhano
Bryan Mckibben
David J. Witter
Original Assignee
Osi Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.
Publication of HUP0400692A2 publication Critical patent/HUP0400692A2/hu
Publication of HUP0400692A3 publication Critical patent/HUP0400692A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát adenozin A1, A2A és A3 receptorokat fajlagosangátló (XI) általános képletű, valamint (1609), (1610) és (1720)képletű vegyületek képezik. A találmány tárgya továbbá ezekalkalmazása az adenozin A1, A2A, és A3 receptorokkal kapcsolatosbetegségek kezelésére alkalmas gyógyszerek előállítására. A (XI)képletben R1NR2 együttes jelentése (442) vagy (443) képletű csoport,vagy R1=H és R2 jelentése hidroxi-ciklohexil-csoport, azzal amegkötéssel, hogy amennyiben -R1NR2 együttes jelentése (442) vagy(443) képletű csoport, akkor R5 jelentése hidrogénatom, metoxi-metil-,metil-, karboxicsoport, -CH2(NC5H8)(OH)(C6H5), -(CH2)2COOH, -CH2OCH2CONH2, -CH2O(CH2)2OH, -CH2OCH2COOH vagy -CH2OCH2COOCH3; vagyamennyiben R1=H és R2 jelentése hidroxi-cikloalkenil-csoport, akkor R5jelentése karboxi-, metixikarbonil-, aminokarbonil-csoport, -CH2(N2C3H3) vagy -CH2O(CH2)2OH. Ó
HU0400692A 2000-12-01 2001-11-30 Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them HUP0400692A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en) 2000-12-01 2001-11-30 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (2)

Publication Number Publication Date
HUP0400692A2 true HUP0400692A2 (hu) 2004-07-28
HUP0400692A3 HUP0400692A3 (en) 2007-09-28

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400692A HUP0400692A3 (en) 2000-12-01 2001-11-30 Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them

Country Status (20)

Country Link
EP (1) EP1347980A4 (hu)
JP (1) JP4579497B2 (hu)
CN (1) CN1263757C (hu)
AP (1) AP1893A (hu)
AU (1) AU2002248151B2 (hu)
BR (1) BR0115847A (hu)
CA (1) CA2430577A1 (hu)
CZ (1) CZ20031831A3 (hu)
EA (1) EA007254B1 (hu)
HU (1) HUP0400692A3 (hu)
IL (1) IL155962A0 (hu)
ME (1) MEP35308A (hu)
MX (1) MXPA03004717A (hu)
NO (1) NO327207B1 (hu)
NZ (1) NZ525885A (hu)
OA (1) OA13295A (hu)
PL (1) PL363245A1 (hu)
WO (1) WO2002057267A1 (hu)
YU (1) YU42703A (hu)
ZA (1) ZA200303729B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
CZ302486B6 (cs) 1998-06-02 2011-06-15 Osi Pharmaceuticals, Inc. N-6-Substituovaný 7-deazapurin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
EP1450811B1 (en) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
CA2469316A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
EA011809B1 (ru) 2001-12-20 2009-06-30 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
CA2502429A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
WO2009047563A1 (en) 2007-10-11 2009-04-16 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EP2247596A2 (en) 2008-01-11 2010-11-10 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
SI2694056T1 (sl) 2011-04-01 2019-12-31 Astrazeneca Ab Terapevtsko zdravljenje
DK2785349T4 (da) 2011-11-30 2023-01-09 Astrazeneca Ab Kombinationsbehandling af cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CN104350056A (zh) * 2012-06-07 2015-02-11 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
CA2915561C (en) 2013-06-21 2020-09-22 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
EA035601B1 (ru) 2013-06-21 2020-07-14 Зенит Эпидженетикс Лтд. Бициклические ингибиторы бромодомена
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
CN108349977B (zh) * 2015-01-20 2021-05-25 无锡福祈制药有限公司 Jak抑制剂
KR102006684B1 (ko) 2015-04-29 2019-08-02 우시 포춘 파마슈티컬 컴퍼니 리미티드 Jak 억제제
CA2983481C (en) 2015-05-29 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase inhibitor
CN105771672B (zh) * 2016-04-18 2018-03-02 天津工业大学 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法
CN108570054B (zh) * 2017-03-07 2021-07-16 广州再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂
KR20210033444A (ko) * 2018-06-04 2021-03-26 엑스사이언티아 엘티디 아데노신 수용체 길항제로서 피라졸로피리미딘 화합물
CN110128316B (zh) * 2019-05-22 2021-08-31 北京大学深圳研究生院 5位取代的β-脯氨酸及其衍生物的制备方法
CN110272373B (zh) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 一种具有选择性的腺苷a1受体拮抗剂及其应用
CN114085178A (zh) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2895961B2 (ja) * 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
CZ302486B6 (cs) * 1998-06-02 2011-06-15 Osi Pharmaceuticals, Inc. N-6-Substituovaný 7-deazapurin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
KR100840727B1 (ko) * 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
EP1450811B1 (en) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof

Also Published As

Publication number Publication date
JP4579497B2 (ja) 2010-11-10
EP1347980A4 (en) 2005-02-09
ZA200303729B (en) 2004-05-14
MEP35308A (en) 2011-02-10
NO327207B1 (no) 2009-05-11
YU42703A (sh) 2006-03-03
OA13295A (en) 2007-04-13
CN1489590A (zh) 2004-04-14
CZ20031831A3 (cs) 2004-05-12
NO20032482D0 (no) 2003-06-02
MXPA03004717A (es) 2004-06-30
AU2002248151B2 (en) 2008-02-21
CA2430577A1 (en) 2002-07-25
BR0115847A (pt) 2004-02-25
NZ525885A (en) 2005-01-28
NO20032482L (no) 2003-07-28
HUP0400692A3 (en) 2007-09-28
CN1263757C (zh) 2006-07-12
IL155962A0 (en) 2003-12-23
EA007254B1 (ru) 2006-08-25
EA200300628A1 (ru) 2003-12-25
AP2003002807A0 (en) 2003-06-30
EP1347980A1 (en) 2003-10-01
WO2002057267A1 (en) 2002-07-25
AP1893A (en) 2008-09-23
PL363245A1 (en) 2004-11-15
JP2004517896A (ja) 2004-06-17

Similar Documents

Publication Publication Date Title
HUP0400692A2 (hu) Szubsztituált 7H-pirrolo[2,3-d]pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
UY24560A1 (es) Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
IS5198A (is) Ný efnasambönd
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
AP2002002561A0 (en) 5-HT receptor ligards and uses thereof.
NZ522326A (en) Adenosine A2A receptor antagonists
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
DOP2002000429A (es) Imidazotriazinas
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
IL114003A (en) 1,4,6-Trisubstituted 1H-pyrrolo[2,3-b]pyridine and 1-H-pyrazolo[3,4-b] pyridine derivatives and pharmaceutical compositions containing them and some intermediates for their preparation
ES2128735T3 (es) Composiciones farmaceuticas que comprenden un antagonista de opiaceos y de sales de calcio y su uso para el tratamiento de patologias en las que intervienen las endorfinas.
ATE211138T1 (de) Beta-carbolin-derivate als melatonin-agonisten, ihre herstellungsverfahren und verwendung als arzneimittel
CR8842A (es) Derivados de pirido-pirimidina, su preparacion, su aplicacion en terapeutica
HUP0402270A2 (hu) [1,2,4]Triazolo[1,5-c]pirimidin-5-il-aminok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények
HUP0302874A2 (hu) Eljárás risperidon előállítására
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.
HUP0203943A2 (hu) Eljárás 9-es helyzetben helyettesített guaninszármazékok előállítására és ezek alkalmazása
HUP9904027A2 (hu) P-Amino-fenol-származékok alkalmazása neurodegeneratív megbetegedések kezelésére alkalmas gyógyszerkészítmények előállítására
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
HUP0100048A2 (hu) Arilszubsztituált piperazinszármazékok, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
DE69927251D1 (de) Verfahren zur herstellung von purinderivaten und dessen zwischenprodukte
AR060418A2 (es) Derivados de azolopirimidina, composicion farmaceutica y uso en la fabricacion de un medicamento

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees